Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2+ Breast Cancer”

3,088 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 3,088 results

Testing effectiveness (Phase 2)WithdrawnNCT03872505
What this trial is testing

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Cedars-Sinai Medical Center
Not applicableActive Not RecruitingNCT04767594
What this trial is testing

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

Who this might be right for
Breast Neoplasms
Pfizer 1,409
Not applicableUnknownNCT04769050
What this trial is testing

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Who this might be right for
Breast Cancer
Fudan University 50
Early research (Phase 1)Ended earlyNCT01238133
What this trial is testing

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+6 more
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Ended earlyNCT00597597
What this trial is testing

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Rush University Medical Center 11
Testing effectiveness (Phase 2)Looking for participantsNCT06361940
What this trial is testing

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Medical College of Wisconsin 100
Not applicableEnded earlyNCT01722890
What this trial is testing

CharactHer. ICORG 12-09, V3

Who this might be right for
HER2-positive Breast CancerTNM Stage II-IV Breast Cancer
Cancer Trials Ireland 130
Not applicableActive Not RecruitingNCT04993625
What this trial is testing

Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study

Who this might be right for
Breast Cancer
Jeong Eon Lee 178
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Testing effectiveness (Phase 2)Study completedNCT01271725
What this trial is testing

LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Who this might be right for
Breast Neoplasms
Boehringer Ingelheim 74
Testing effectiveness (Phase 2)Study completedNCT00077376
What this trial is testing

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
National Cancer Institute (NCI) 61
Testing effectiveness (Phase 2)UnknownNCT05340413
What this trial is testing

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Who this might be right for
HER2-negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer
SOLTI Breast Cancer Research Group 63
Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Not applicableLooking for participantsNCT06035016
What this trial is testing

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

Who this might be right for
HER2-positive Breast CancerEarly-stage Breast Cancer
Peking Union Medical College Hospital 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06750848
What this trial is testing

Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jundong Wu 48
Testing effectiveness (Phase 2)Study completedNCT04224272
What this trial is testing

ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Who this might be right for
HER2+/HR+ Breast Cancer
Jazz Pharmaceuticals 51
Large-scale testing (Phase 3)Not Yet RecruitingNCT07005557
What this trial is testing

Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

Who this might be right for
Breast CancerAdjuvant Therapy
Fudan University 1,244
Not applicableUnknownNCT04683757
What this trial is testing

The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Ying Wang 288
Testing effectiveness (Phase 2)WithdrawnNCT00397501
What this trial is testing

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerCognitive/Functional Effects+2 more
OHSU Knight Cancer Institute
Large-scale testing (Phase 3)Looking for participantsNCT06680921
What this trial is testing

SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 460
Load More Results